<DOC>
	<DOC>NCT02623257</DOC>
	<brief_summary>The study aims to explore the prevalence of EGFR mutations assessed with ctDNA samples in advanced NSCLC, who had received ≤ 1 prior systemic chemotherapy regimens.</brief_summary>
	<brief_title>EGFR Mutations on ctDNA in Patients With Advanced NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically confirmed stage IIIB/IV NSCLC; Patient had received ≤ 1 prior systemic chemotherapy regimens; Provision of blood (plasma) sample for ctDNA testing; Patient must be able to comply with the protocol; Prior received ≥2 systemic chemotherapy regimens; As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease); Histologically confirmed small cell lung cancer or other metastatic tumors; Patient with no histologic or cytological diagnosis;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>circulating tumor DNA</keyword>
	<keyword>amplification refractory mutation system</keyword>
</DOC>